Size-Controlled Nucleic Acid Fragments Using Active-Inactive Transposomes

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing nucleic acid sequencing methods result in a broad size distribution of fragments, leading to inefficiencies in sequencing data generation and waste of nucleic acid samples, particularly in low concentration samples.

Innovation Solution

A transposome complex comprising a combination of active and inactive transposomes is used to generate size-controlled nucleic acid fragments by controlling the length of fragments through the ratio and arrangement of active and inactive transposomes, ensuring fragments are within the optimal size range for sequencing instruments.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Manufacturing precision

If mechanical fragmentation methods (sonicator, nebulizer, or nuclease) are used to generate DNA fragments, then DNA can be fragmented into smaller pieces, but the fragments exhibit a broad size distribution leading to waste of nucleic acid samples

Engineering Contradiction:
Improvefragment size controlVSAvoidnucleic acid sample waste
Core Design Contradiction:
Manufacturing precisionVSLoss of substance

Solution Approach 1:

The patent changes the key parameter of transposome composition by incorporating inactive transposomes alongside active transposomes. This parameter change enables precise control over fragment size distribution, producing a narrow size range that matches sequencing instrument requirements and reduces sample waste

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

Inactive transposomes serve as intermediaries that control the fragmentation process without catalyzing the reaction. They act as spatial regulators that define fragment boundaries, enabling size control while the active transposomes perform the actual fragmentation and tagging

Inventive Principle:
Principle #24Intermediary (Mediator)

2Ease of manufacture

If transposomes are used to tag and fragment DNA simultaneously, then library preparation is simplified, but the fragments still exhibit broad size distribution requiring additional size-selection steps

Engineering Contradiction:
Improvelibrary preparation simplicityVSAvoidadditional size-selection steps
Core Design Contradiction:
Ease of manufactureVSDevice complexity

Solution Approach 1:

By adjusting the ratio and composition of active to inactive transposomes in the reaction mixture, the patent optimizes fragment size distribution to match sequencing instrument requirements, eliminating the need for additional size-selection steps while maintaining simplified library preparation

Inventive Principle:
Principle #35Parameter changes

3Quantity of substance

If a broad size distribution of fragments is generated, then more nucleic acid material is available for sequencing, but sequencing efficiency decreases and data quality is reduced

Engineering Contradiction:
Improvenucleic acid material availabilityVSAvoidsequencing efficiency
Core Design Contradiction:
Quantity of substanceVSProductivity

Solution Approach 1:

The patent changes the fragmentation parameter from random mechanical shearing to controlled transposome-mediated cleavage with defined size distribution. This produces fragments within the optimal size range for sequencing instruments, maximizing sequencing efficiency and data quality while maintaining adequate material availability

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach reduces the amount of nucleic acid discarded and improves sequencing efficiency by generating fragments of uniform size, thereby enhancing data quality and reducing the need for additional size-selection steps.

Implementation Method 1

The use of transposomes, protein-DNA complexes of a transposase and transposon sequences that tag and fragment ('tagment') DNA by transposition

Methodology Applied
Scientific EffectTransposition:

Implementation Method 2

hybridizing at least one linking transposome to the initiator transposome via an at least partially double-stranded linking adaptor

Methodology Applied
Scientific EffectHybridization:

Data Source

PatentUS20250320487A1Preparation Of Size-Controlled Nucleic Acid Fragments
Publication Date: 2025.10.16 ILLUMINA INC
  • US20250320487A1 patent drawing
  • US20250320487A1 patent drawing
  • US20250320487A1 patent drawing

AI summary

A transposome complex capable of producing size-controlled nucleic acid fragments is described herein. In some embodiments, the transposome complex includes multiple inactive transposomes with active transposomes on both ends of the multiple inactive transposomes. Applications, uses, and variations of the disclosed transposome complex include, but are not limited to, library preparation for a nucleic acid and tuning the length of the transposome complex to produce nucleic acid fragments of predetermined or desired lengths.